Company / Capital Returned to Shareholders
CUMBERLAND PHARMACEUTICALS INC Capital Returned to Shareholders History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Returned to Shareholders
$263.5K
FY2025
5-year range
$263.5K / $3.5M
FY2021-FY2025
Trend
-64.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Capital Returned to Shareholders has declined for 4 consecutive years, from $3M in FY2021 to $263,478 in FY2025.
Based on SEC 10-K filings.
$263,478 in FY2025 with a 5-year CAGR of -32.3%.
Declined from $1M to $263,478 over the past 2 years.
Capital Returned to Shareholders over time
Growth rates
- 3-Year CAGR
- -42.5%
- 5-Year CAGR
- -32.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- CUMBERLAND PHARMACEUTICALS INC's capital returned to shareholders has declined for 4 consecutive years.
- 5-year CAGR of -32.3%, indicating a declining trend.
- In FY2025, capital returned to shareholders decreased 64.4% year-over-year.
- Peak capital returned to shareholders was recorded in FY2017.
Company context
Key Data Points
- Altman Z-Score 0.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital Returned to ShareholdersValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $263.5K | -64.4% |
| FY2024 | $740.5K | -29.7% |
| FY2023 | $1.1M | -24.1% |
| FY2022 | $1.4M | -60.3% |
| FY2021 | $3.5M | +88.8% |
| FY2020 | $1.9M | -47.0% |
| FY2019 | $3.5M | +38.6% |
| FY2018 | $2.5M | -52.8% |
| FY2017 | $5.3M | +23.7% |
| FY2016 | $4.3M | -10.1% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026